Table 1.1 Trachoma control delivery in at-risk* communities by jurisdiction, Australia 2017 Number of communities Northern Territory South Australia Western Australia Queensland Total At risk * (A) 68 18 41 3 130 Requiring screening for trachoma (B) 30 18 34 3 85 Screened for trachoma (C) 29 18 34 3 84 Requiring treatment without screening (D) † 23 0 1 0 24 Received treatment without screening (E) † 22 0 1 0 23 Screened and/or treated for trachoma (F = C+E) 51 18 35 3 107 Requiring neither screening or treatment for trachoma 15 0 6 0 21 * As defined by each jurisdiction † As per Guidelines
1.3 Number and proportion * of at-risk communities according to level of trachoma prevalence in children aged 5-9 years, Australia 2007-2017 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Communities at-risk † 229 233 232 244 203 196 183 177 157 150 130 Communities not screened ‡ 102 107 116 89 53 9 20 0 8 8 1 Number of communities § 123 121 116 152 152 187 163 177 149 142 129 ≥20% 32 26% 54 45% 26 22% 44 29% 21 14% 15 8% 14 9% 17 10% 16 11% 15 11% 17 13% ≥10% but <20% 22 18% 14 12% 13 11% 23 15% 20 13% 13 7% 20 12% 36 20% 27 18% 29 20% 30 23% ≥5% but <10% 11 9% 14 12% 12 10% 15 10% 20 13% 20 11% 21 13% 12 7% 16 11% 12 8% 13 10% >0% but <5% 7 6% 12 10% 24 21% 16 11% 19 13% 24 13% 17 10% 13 7% 16 11% 21 15% 19 15% 0% 51 41% 27 22% 41 35% 54 36% 72 47% 115 61% 91 56% 99 56% 74 50% 65 46% 50 39% * Based on current or most recent year † As defined annually by each jurisdiction ‡ Or treated as required per Guidelines § Screened or receiving ongoing annual treatment as per Guidelines
Table 1.4 Treatment strategies by jurisdiction, Australia 2017 Number of communities Northern Territory South Australia Western Australia Queensland Total Required treatment for trachoma 34 15 25 0 74 Treated for trachoma 33 15 25 0 73 Screened and treated 11 15 24 0 50 Received treatment without screening 22 0 1 0 23 Received 6-monthly treatment 7 0 1 0 8 Did not require treatment 34 3 16 3 56 Treated active cases and households 9 15 4 0 28 Treated the whole of community 22 0 21 0 43 Not treated according to CDNA guidelines 1 0 0 0 1
Table 1.5 Trachoma treatment coverage, Australia 2017 Northern Territory South Australia Western Australia Queensland † Total Age group (years) 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All Requiring treatment for active trachoma 1 29 5 N/A 35 4 15 8 N/A 27 13 47 17 N/A 77 0 0 0 N/A 0 18 91 30 N/A 139 Received treatment for active trachoma 1 29 5 N/A 35 4 15 8 N/A 27 13 47 17 N/A 77 N/A 18 91 30 N/A 139 Received treatment for active trachoma (%) 100 100 100 N/A 100 100 100 100 N/A 100 100 100 100 N/A 100 N/A 100 100 100 N/A 100 Estimated community members* requiring treatment 847 1053 965 5522 8387 16 25 16 112 169 250 399 323 1698 2670 1113 1477 1304 7332 11226 Number of community members* who received treatment 707 978 829 4095 6609 13 24 15 107 159 232 376 298 1484 2390 952 1378 1142 5686 9158 Estimated community members who received treatment (%) 83 93 86 74 79 81 96 94 96 94 93 94 92 87 90 86 93 88 78 82 Total number of doses of azithromycin delivered 708 1007 834 4095 6644 17 39 23 107 186 245 423 315 1484 2467 970 1469 1172 5686 9297 14 14 14
Table 2.4 Treatment strategies by region, Northern Territory 2017 Alice Springs Remote Barkly Darwin Rural East Arnhem Katherine Total Required treatment for trachoma 20 7 1 0 6 34 Treated for trachoma* 20 7 1 0 5 33 Screened and treated 3 7 1 0 0 11 Received treatment only 17 0 0 0 5 22 Received treatment 6 0 0 0 1 7 Did not require treatment 4 6 6 7 11 34 Treated active trachoma and households 1 7 1 0 0 9 Community-wide treatment 17 0 0 0 5 22 Not treated according to CDNA Guidelines* 0 0 0 0 1 1 * One community in the Katherine region did not receive the treatment which was required by the CDNA Guidelines due to staffing shortages
Table 2.5 Trachoma treatment coverage by region,* Northern Territory 2017 Alice Springs Remote Barkly Darwin Rural East Arnhem Katherine 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All 0-4 5-9 15+ All Requiring treatment for active trachoma 1 14 2 N/A 17 0 12 2 N/A 14 0 3 0 N/A 3 0 0 1 N/A 1 0 0 0 N/A 0 1 29 5 N/A 35 Received treatment for active trachoma 1 14 2 N/A 17 0 12 2 N/A 14 0 3 0 N/A 3 0 0 1 N/A 1 0 0 0 N/A 0 1 29 5 N/A 35 Received treatment for active trachoma (%) 100 100 100 N/A 100 N/A 100 100 N/A 100 N/A 100 N/A N/A 100 N/A N/A 100 N/A 100 N/A N/A N/A N/A N/A 100 100 100 N/A 100 Estimated community members* requiring treatment 676 816 748 4472 6712 19 14 11 67 111 5 3 9 19 36 0 1 1 3 5 147 219 196 961 1523 847 1053 965 5522 8387 Number of community members* who received treatment 552 749 627 3176 5104 19 14 11 67 111 4 3 9 16 32 0 1 1 3 5 132 211 181 833 1357 707 978 829 4095 6609 Estimated community members who received treatment (%) 82 92 84 71 76 100 100 100 100 100 80 100 100 84 89 N/A 100 100 100 100 90 96 92 87 89 83 93 86 74 79 Total number of doses of azithromycin delivered 553 763 629 3176 5121 19 26 13 67 125 4 6 9 16 35 0 1 2 3 6 132 211 181 833 1357 708 1007 834 4095 6644 Estimated overall treatment coverage (%) 82 92 84 71 76 100 100 100 100 100 80 100 100 84 90 N/A 100 100 100 100 90 96 92 87 89 83 93 86 74 79 * Includes household contacts and community members requiring and receiving mass drug administration (MDA)
Requiring neither screening or treatment for trachoma (G=A-B-D) 0 0 0 0 * As defined by each jurisdiction † As per guidelines APY: Anangu Pitjantjatjara Yankunytjatjara
Table 3.2 Trachoma screening coverage, trachoma prevalence and clean face prevalence by region, South Australia 2017 APY Lands Eyre and Western Far North Total Number of communities screened 9 4 5 18 Age group (years) 0-4 5-9 10-14 0-14 0-4 5-9 10-14 0-14 0-4 5-9 10-14 0-14 0-4 5-9 10-14 0-14 Children examined for clean face 212 220 261 693 55 109 98 262 3 269 64 336 270 598 423 1291 Children with face 146 165 248 559 53 108 98 259 2 253 64 319 201 526 410 1137 Clean face prevalence (%) 69 75 95 81 96 99 100 99 67 94 100 95 74 88 97 88 Estimated number* of Aboriginal children in communities† 265 232 278 775 198 173 162 533 300 337 327 964 763 742 767 2272 Children screened for trachoma 212 220 261 693 55 109 98 262 2 269 63 334 269 598 422 1289 Trachoma screening coverage (%) 80 95 94 89 28 63 60 49 0.7 80 19 35 35 81 55 57 Children with active trachoma† 2 8 7 17 2 4 1 7 0 3 0 3 4 15 8 27 Observed prevalence of active trachoma‡ (%) 0.9 3.6 2.7 2.5 3.6 3.7 1.0 2.7 0.0 1.1 0.0 0.9 1.5 2.5 1.9 2.1 Estimated prevalence of active trachoma‡ (%) N/A 3.6 N/A N/A N/A 3.7 N/A N/A N/A 1.1 N/A N/A N/A 2.5 N/A N/A Overall prevalence of active trachoma‡ (%) N/A 3.6 N/A N/A N/A 1.5 N/A N/A N/A 1.0 N/A N/A N/A 1.6 N/A N/A * ABS estimate † Communities that were screened for trachoma in 2017 ‡ Methods of calculating the different prevalence rates on page 15 APY: Anangu Pitjantjatjara Yankunytjatjara
Table 3.3 Number and proportion* of at-risk communities according to level of trachoma prevalence in children aged 5-9 years, South Australia 2007-2017 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Communities at-risk † 68 72 72 72 46 38 22 21 19 19 18 Communities not screened ‡ 60 61 60 60 27 2 6 0 0 0 0 Number of communities § 8 11 12 11 19 36 16 21 19 19 18 ≥20% 2 25% 0 0% 3 25% 3 27% 2 11% 1 3% 2 13% 1 5% 2 11% 1 5% 1 5% ≥10% but <20% 2 25% 1 9% 2 17% 1 9% 3 16% 1 3% 3 19% 9 43% 3 16% 1 5% 1 6% ≥5% but <10% 2 25% 2 18% 1 8% 0 0% 2 11% 1 3% 1 6% 0 0% 9 47% 2 11% 3 17% >0% but <5% 0 0% 1 9% 1 8% 0 0% 1 5% 4 11% 0 0% 1 5% 1 5% 11 58% 10 56% 0% 2 25% 7 64% 5 42% 7 64% 11 58% 29 81% 10 63% 10 48% 4 21% 4 21% 3 17% * on current or most recent year † As defined annually by each jurisdiction ‡ Or treated as required per Guidelines § Screened or receiving ongoing annual treatment as per Guidelines
Table 3.4 Treatment strategies by region, South Australia 2017 APY Lands Eyre and Western Far North Total Required treatment for trachoma 9 3 3 15 Treated for trachoma* 9 3 3 15 Screened and treated 9 3 3 15 Received treatment only 0 0 0 0 Received 6-monthly treatment 0 0 0 0 Did not require treatment 0 1 2 3 Treated active trachoma and households 9 3 3 15 Community wide treatment 0 0 0 0 Not treated according to CDNA Guidelines* 0 0 0 0 * In 2017 APY aggregated 9 communities into one community for presentation of data; details of the specific number of communities requiring treatment or treated were not supplied APY: Anangu Pitjantjatjara Yankunytjatjara
Table 4.5 Trachoma treatment coverage by region, Western Australia 2017 Goldfields Kimberley Midwest Pilbara Total 0-4 5-9 10-14 15+ All 0-4 5-9 10-14 15+ All 0-4 5-9 10-14 15+ All 0-4 5-9 10-14 15+ All 0-4 5-9 10-14 15+ All Requiring treatment for active trachoma 10 28 10 N/A 48 2 8 0 N/A 10 0 3 1 N/A 4 1 8 6 N/A 15 13 47 17 N/A 77 Received treatment for active trachoma 10 28 10 N/A 48 2 8 0 N/A 10 0 3 1 N/A 4 1 8 6 N/A 15 13 47 17 N/A 77 Received treatment for active trachoma (%) 100 100 100 N/A 100 100 100 N/A N/A 100 N/A 100 100 N/A 100 100 100 100 N/A 100 100 100 100 N/A 100 Estimated community members* requiring treatment 135 164 147 900 1346 36 78 76 315 505 57 102 54 259 472 22 55 46 224 347 250 399 323 1698 2670 Number of community members* who received treatment 124 149 133 782 1188 34 74 69 268 445 52 98 51 219 420 22 55 45 215 337 232 376 298 1484 2390 Estimated community members who received treatment (%) 92 91 90 87 88 94 95 91 85 88 91 96 94 85 89 100 100 98 96 97 93 94 92 87 90 Total number of doses of azithromycin delivered 134 177 143 782 1236 36 82 69 268 455 52 101 52 219 424 23 63 51 215 352 245 423 315 1484 2467 Estimated overall treatment coverage (%) 92 92 91 87 89 95 95 91 85 88 91 96 95 85 89 100 100 98 96 97 93 95 93 87 90 * Includes household contacts and community members requiring/receiving mass drug administration (MDA)
Social marketing Print material/mass media 1 Sporting/community events 2 Other Target audience Health professionals/staff 4 Children 1 Teachers/childcare/preschool 1 Caregivers/parents 1 Community members 2 Community educators/health promoters Interagency members 1 Frequency of health promotion activities Once Occasional * 5 Regular† 2 Ongoing/routine 2 * 2-4 times per year. † 5-12 times per year. References